Trial of Ateronon in Patients With Coronary Disease to Evaluate Its Effectiveness in Assessing the Risk Factors of Atherosclerosis

Omicron Pharmaceuticals1 site in 1 country100 target enrollmentMay 2011

InterventionsAteronon

Overview

Phase: Phase 3
Intervention: Ateronon
Conditions: Atherosclerosis
Sponsor: Omicron Pharmaceuticals
Enrollment: 100
Locations: 1
Primary Endpoint: to evaluate the effectiveness of Ateronon in inhibiting atherogenic lipid oxidation in patients with demonstrated coronary disease
Status: Completed
Last Updated: 12 years ago

This is a trial of Ateronon in Patients with Coronary Disease to Evaluate its Effectiveness in Assessing the Risk Factors of Atherosclerosis.

Registry

clinicaltrials.gov

Start Date

May 2011

End Date

December 2011

Last Updated

12 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Sponsor

Omicron Pharmaceuticals

Responsible Party

Sponsor

•Women who are pregnant, nursing or intend pregnancy during the period of treatment
•Known milk, soy or whey allergy

Intervention: Ateronon

to evaluate the effectiveness of Ateronon in inhibiting atherogenic lipid oxidation in patients with demonstrated coronary disease

Time Frame: Baseline and 3 months

to evaluate the potential effectiveness of Ateronon in lowering pulse rate as well systolic and diastolic blood pressure in patients with demonstrated coronary disease(Baseline and 3 months)